A nose spray before treatment: could naloxone speed up opioid recovery for fentanyl users?

NCT ID NCT06089707

Ongoing Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether giving naloxone — the opioid-overdose reversal drug — just before buprenorphine can help people who use fentanyl start addiction treatment more quickly and with less discomfort. The study enrolls a small group of adults with opioid use disorder who test positive for fentanyl. Researchers will measure withdrawal severity, how long it takes to reach a stable buprenorphine dose, and whether participants find the method acceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: naloxone nasal spray followed by buprenorphine
What this could lead to: If this approach works, it could offer a faster, less uncomfortable way to start buprenorphine treatment for people dependent on fentanyl.
What could go wrong: This is a very small early-phase trial with only 3 participants, so results may not apply broadly. The method could still cause withdrawal symptoms or be poorly tolerated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Johns Hopkins School of Medicine

Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.